Enterprise Solutions

  1. Scaling Biologics With Confidence: Late-Stage To Commercial 8/17/2026

    Four real-world biologics case studies show how tech transfers, scale-ups, and CGMP manufacturing are executed without compromising critical quality attributes or regulatory timelines.

  2. Laboratory Freeze-Thaw Unit | RoSS.pFTU Lab-Scale 8/17/2026

    A plate-based lab-scale freeze-thaw unit designed for controlled, cGMP-compliant freezing and thawing of single-use bioprocess containers from 1mL to 10L.

  3. All-In-One Fully Automated Cell Therapy Development & Production Systems 8/15/2026

    Closed, automated processing streamlines cell manufacturing from isolation to final fill. Modular workflows lower operational risks while ensuring regulatory compliance.

  4. Cell Processing Systems Powered By Flexible Automation 8/15/2026

    Closed, automated processing protects cell viability from PBMC isolation to final fill. Built-in controls and low-shear flow maintain precision and regulatory compliance.

  5. Automated Magnetic Cell Sorting 8/15/2026

    Streamline cell separation using automated magnetic sorting with real-time process monitoring, Grade C sterile processing, and high-yield, medium-based elution.

  6. One Partner, Every Step Of Your ADC Program 8/15/2026

    Most ADC programs rely on multiple vendors. We provide antibody development, payload chemistry, and conjugation under one quality system, from discovery through cGMP supply.

  7. Scalable Freezing And Thawing For Process Development And Manufacturing 8/13/2026

    RoSS.pFTU is a plate-based freeze-thaw platform designed for controlled, scalable freezing and thawing of biopharmaceutical drug substances. Compatible with single-use bags and bottles from multiple suppliers, the platform supports a vendor-independent freeze/thaw strategy from process development through commercial manufacturing.

  8. Accelerating Complex Injectable Programs 8/13/2026

    Accelerate complex injectable development with integrated capabilities in lipid nanoparticles, liposomes, sterile products, and combination devices.

  9. Comprehensive ASO And siRNA Capabilities 8/13/2026

    BE Biosol is expanding its biologics portfolio to include future capabilities in antisense oligonucleotide and siRNA technologies. 

  10. From ADC Development To Commercial Readiness 8/13/2026

    Designed for highly potent compounds, the platform supports ADC development from early-stage research through GMP manufacturing and commercial scale-up.